| Protein Name: | NADH-cytochrome b5 reductase (P00387) |
|---|---|
| Gene Name: | VCL |
| Description: | NADH-cytochrome b5 reductase (EC 1 6 2 2) (B5R) (Diaphorase-1) (Cytochrome b5 reductase 3) [Contains: NADH-cytochrome b5 reductase membrane-bound form; NADH-cytochrome b5 reductase soluble form] |
| PDB ID: | 1M91 |
| Protein Family: | |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Indomethacin | Selective Effect Of A P-Chlorophenyl Moiety | Indomethacin in vitro also caused a loss of cytochrome b5, NADH-cytochrome b5 reductase, NADPH-cytochrome c reductase and epoxide hydrolase activities, but an activation of UDP-glucuronyltransferase,which leads to selective effect of a p-chlorophenyl moiety [ ADR Type 1 ] | Denaturation of cytochrome P-450 by indomethacin and other non-steroidal anti-inflammatory drugs: evidence for a surfactant mechanism and a selective effect of a p-chlorophenyl moiety |
| RB90740(fused pyrazine mono-N-oxide bioreductive drugs) | Hypoxic Toxicity | Relationship between the intracellular levels of P450 reductase and cytochrome b5 reductase and the hypoxic toxicity of RB90740. [ ADR Type 1 ] | Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase |
| Zidovudine | Mitochondrial Toxicity | AZT induced a dose-dependent inhibition of both NADH-linked respiration in intact mitochondria and NADH-cytochrome c reductase activity in freeze-thawed mitochondrial preparations,suggesting its mechanism of mitochondrial toxicity. [ ADR Type 1 ] | AZT causes tissue-specific inhibition of mitochondrial bioenergetic function |
This panel provides information on drug category
| Toxicity | Source |
|---|